Home・Akciju saraksts・REGENXBIO Inc

REGENXBIO Inc

Slēgts

SektorsVeselības aprūpe

10.3 4.15

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.23

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	-23M -90M
Pārdošana	-24M 6.4M
EPS	-1.72
Peļņas marža	-1,408.588
Darbinieki	371
EBITDA	-14M -77M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+160.78% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	101M 622M
Iepriekšējā atvēršanas cena	6.15
Iepriekšējā slēgšanas cena	10.3

Ziņu noskaņojums

By Acuity

50%

151 / 340 Rangs Healthcare

REGENXBIO Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. jūl. 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

2026. g. 30. jūl. 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

2026. g. 29. jūl. 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

2026. g. 28. jūl. 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

2026. g. 27. jūl. 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

2026. g. 24. jūl. 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

2026. g. 22. jūl. 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

2026. g. 21. jūl. 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

2026. g. 20. jūl. 19:31 UTC

Event

News

Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Salīdzinājums

Cenas izmaiņa

REGENXBIO Inc Prognoze

Cenas mērķis

By TipRanks

160.78% augšup

Prognoze 12 mēnešiem

Vidējais 25.27 USD 160.78%

Augstākais 45 USD

Zemākais 10 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi REGENXBIO Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam REGENXBIO Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

151 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.